The RPRFamide is a neurotoxin from the conorfamide family of neuropeptides, found in the venom of cone snails.

RPRFamide
Identifiers
3D model (JSmol)
  • InChI=1S/C26H43N11O4/c27-17(9-4-12-33-25(29)30)24(41)37-14-6-11-20(37)23(40)35-18(10-5-13-34-26(31)32)22(39)36-19(21(28)38)15-16-7-2-1-3-8-16/h1-3,7-8,17-20H,4-6,9-15,27H2,(H2,28,38)(H,35,40)(H,36,39)(H4,29,30,33)(H4,31,32,34)/t17-,18-,19-,20-/m0/s1
    Key: ZCURAMQBXXPVOI-MUGJNUQGSA-N
  • N[C@@]([H])(CCCNC(=N)N)C(=O)N1[C@@]([H])(CCC1)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)N
Properties
C26H43N11O4
Molar mass 573.703 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Etymology and source

edit

The RPRFamide is a toxin that originates in the carnivorous marine cone snail Conus textile. They are a predatory species that mainly live in tropical waters.[1] The venom of marine cone snails contains a diverse variety of toxins, which include conotoxins.

RPRFamide belongs to the family of conotoxins, more specifically to the conorfamide family or RFamide family which are peptides that target neuronal ion channels in their prey.[2]

Chemistry

edit

The sequence for this toxin is identified as RPRF (R = arginine, P = proline, and F = phenylalanine). An amide group (-NH2) is located at the terminal end (C-terminus). The presence of this group is paramount for its biological activity as it enhances its interaction with ion channels.[3]

The short length, the C-terminal Arg–Phe–NH2 (RFa) motif, and the lack of cysteines clearly distinguish these peptides from conotoxins and categorise them as cono-RFamides.[3]

Target

edit

Two main molecular targets have been discovered for RPRFamide. Firstly, it targets the acid sensing ion channel 3 (ASIC3), involved in the pain pathway. Secondly, it can target and inhibit nicotinic acetylcholine receptors (nAChRs), specifically the alpha-7 subtype.[3]

Mode of action

edit

The RPRFamide peptide modulates ASIC3, a proton-gated ion channel that is sensitive to acidic conditions and involved in pain perception. This channel is a proton-gated sodium channel involved in nociception in response to acidic environments in a tissue, such as muscle fatigue.[4] The toxin enhances ASIC3 currents, leading to increased pain signalling, particularly in response to acidic stimuli. This explains why RPRFamide can induce pain, particularly muscle pain, through the activation of ASIC3 channels.[5] The peptide delays the desensitization of ASIC3 channels, keeping them open longer and allowing sustained ion flow, which increases sensitivity to pain stimuli and prolongs the nociceptive effect.[4]

Studies show that injecting cono-RFamide into mice muscle leads to increased acid induced pain.[3][5] Additionally, studies showed that RPRFamide causes an increase in excitability of dorsal root ganglion (DRG) neurons.[5]

The RPRFamide also modulates nACh receptors by inhibiting them, specifically the alpha-7 and muscle-type nAChRs. These receptors are ligand-gated ion channels that mediate fast synaptic transmission in the nervous system and are involved in neuromuscular function.[3] The toxin’s inhibitory effect prevents the influx of ions that would normally result from acetylcholine binding, disrupting neurotransmission and impairing muscle contraction, depending on the receptor subtype.[3]

Toxicity

edit

The toxicity of RPRFamide has yet to be assessed in humans. However, available literature suggests that ASIC3 channels are expressed in muscle pain receptors, leading to extreme, long-lasting pain when injected into muscle tissue in mice, particularly when administered with an acidic solution.[5]

Treatment

edit

Currently, no available literature describes a method to counteract the neurotoxic activity of RPRFamide.

Therapeutic use

edit

The therapeutic potential of RPRFamide has yet to be fully assessed. Some authors have discussed the neurotoxin's modulation of ASIC3 and nAChRs receptors, suggesting that further research could explore its role in pain modulation, including potential treatments for chronic pain.[3][4]

References

edit
  1. ^ Northfield, Susan E.; Wang, Conan K.; Schroeder, Christina I.; Durek, Thomas; Kan, Meng-Wei; Swedberg, Joakim E.; Craik, David J. (2014). "Disulfide-rich macrocyclic peptides as templates in drug design". European Journal of Medicinal Chemistry. 77: 248–257. doi:10.1016/j.ejmech.2014.03.011.
  2. ^ Kapil, Sasha; Hendriksen, Stephen; Cooper, Jeffrey S. (2024), "Cone Snail Toxicity", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 29262115, retrieved 2024-10-22
  3. ^ a b c d e f g Jin, Ai-hua; Cristofori-Armstrong, Ben; Rash, Lachlan D.; Román-González, Sergio Agustín; Espinosa, Roberto Arreguín; Lewis, Richard J.; Alewood, Paul F.; Vetter, Irina (2019). "Novel conorfamides from Conus austini venom modulate both nicotinic acetylcholine receptors and acid-sensing ion channels". Biochemical Pharmacology. 164: 342–348. doi:10.1016/j.bcp.2019.04.025. PMID 31028742.
  4. ^ a b c Reiners, Melissa; Margreiter, Michael A.; Oslender-Bujotzek, Adrienne; Rossetti, Giulia; Gründer, Stefan; Schmidt, Axel (2018). "The Conorfamide RPRFa Stabilizes the Open Conformation of Acid-Sensing Ion Channel 3 via the Nonproton Ligand–Sensing Domain". Molecular Pharmacology. 94 (4): 1114–1124. doi:10.1124/mol.118.112375. ISSN 0026-895X.
  5. ^ a b c d Reimers, Catharina; Lee, Cheng-Han; Kalbacher, Hubert; Tian, Yuemin; Hung, Chih-Hsien; Schmidt, Axel; Prokop, Lea; Kauferstein, Silke; Mebs, Dietrich; Chen, Chih-Cheng; Gründer, Stefan (2017-04-25). "Identification of a cono-RFamide from the venom of Conus textile that targets ASIC3 and enhances muscle pain". Proceedings of the National Academy of Sciences. 114 (17): E3507–E3515. doi:10.1073/pnas.1616232114. ISSN 0027-8424. PMC 5410773. PMID 28396446.